Anzeige
Mehr »
Login
Montag, 24.02.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
KI-Wunder? Diese Aktie verachtfacht sich nach Deepseek R1-Integration!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 753718 | ISIN: US98956P1021 | Ticker-Symbol: ZIM
Tradegate
21.02.25
18:32 Uhr
99,96 Euro
-0,29
-0,29 %
Branche
Gesundheitswesen
Aktienmarkt
S&P 500
1-Jahres-Chart
ZIMMER BIOMET HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
ZIMMER BIOMET HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
99,88100,6509:30
99,88100,6509:30
GlobeNewswire (Europe)
328 Leser
Artikel bewerten:
(2)

Bactiguard Holding AB: Zimmer Biomet terminates agreement for multiple orthopedic product segments - trauma agreement remains in effect

Finanznachrichten News

Zimmer Biomet has informed Bactiguard that they terminate the license agreement signed in 2022 covering multiple orthopedic product segments. The reason stated is the more complex and lengthier path with the US Food and Drug Administration (FDA) than initially expected by Zimmer Biomet.

There will be no negative financial impact for Bactiguard for 2024 related to this termination. Bactiguard is in dialogue with the team at Zimmer Biomet to evaluate further details and the impact of the termination and will revert with more information once available.

The partnership with Zimmer Biomet within the trauma product segment, related to the agreement signed in 2019, remains in effect.

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below, 2024-10-02 at 10:40 CET.

For further information, please contact:
Patrick Bach, CFO +46 761 295 911
Nina Nornholm, Head of Communications & Investor Relations +46 708 550 356

About Bactiguard
Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The company's unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard's infection prevention technology and solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine.

Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices and sell them under their own brand or co-branded with Bactiguard. The company also has a portfolio of wound management products.

Bactiguard is headquartered in Stockholm and listed on Nasdaq Stockholm.

Read more about Bactiguard: www.bactiguard.com
Follow Bactiguard on LinkedIn


© 2024 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.